These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

285 related items for PubMed ID: 22871739

  • 1. E2F1 confers anticancer drug resistance by targeting ABC transporter family members and Bcl-2 via the p73/DNp73-miR-205 circuitry.
    Alla V, Kowtharapu BS, Engelmann D, Emmrich S, Schmitz U, Steder M, Pützer BM.
    Cell Cycle; 2012 Aug 15; 11(16):3067-78. PubMed ID: 22871739
    [Abstract] [Full Text] [Related]

  • 2. Kinetic modeling-based detection of genetic signatures that provide chemoresistance via the E2F1-p73/DNp73-miR-205 network.
    Vera J, Schmitz U, Lai X, Engelmann D, Khan FM, Wolkenhauer O, Pützer BM.
    Cancer Res; 2013 Jun 15; 73(12):3511-24. PubMed ID: 23447575
    [Abstract] [Full Text] [Related]

  • 3. Mdm2 inhibition induces apoptosis in p53 deficient human colon cancer cells by activating p73- and E2F1-mediated expression of PUMA and Siva-1.
    Ray RM, Bhattacharya S, Johnson LR.
    Apoptosis; 2011 Jan 15; 16(1):35-44. PubMed ID: 20812030
    [Abstract] [Full Text] [Related]

  • 4. GRAMD4 mimics p53 and mediates the apoptotic function of p73 at mitochondria.
    John K, Alla V, Meier C, Pützer BM.
    Cell Death Differ; 2011 May 15; 18(5):874-86. PubMed ID: 21127500
    [Abstract] [Full Text] [Related]

  • 5. p73 and IGF1R Regulate Emergence of Aggressive Cancer Stem-like Features via miR-885-5p Control.
    Meier C, Hardtstock P, Joost S, Alla V, Pützer BM.
    Cancer Res; 2016 Jan 15; 76(2):197-205. PubMed ID: 26554827
    [Abstract] [Full Text] [Related]

  • 6. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
    Ambrosini G, Sambol EB, Carvajal D, Vassilev LT, Singer S, Schwartz GK.
    Oncogene; 2007 May 24; 26(24):3473-81. PubMed ID: 17146434
    [Abstract] [Full Text] [Related]

  • 7. Overexpression of E2F1 in human gastric carcinoma is involved in anti-cancer drug resistance.
    Yan LH, Wei WY, Cao WL, Zhang XS, Xie YB, Xiao Q.
    BMC Cancer; 2014 Dec 03; 14():904. PubMed ID: 25466554
    [Abstract] [Full Text] [Related]

  • 8. Camptothecin induces p53-dependent and -independent apoptogenic signaling in melanoma cells.
    Rudolf E, Rudolf K, Cervinka M.
    Apoptosis; 2011 Nov 03; 16(11):1165-76. PubMed ID: 21809047
    [Abstract] [Full Text] [Related]

  • 9. Deregulated expression of E2F1 promotes proteolytic degradation of tumor suppressor p73 and inhibits its transcriptional activity.
    Ozaki T, Okoshi R, Ono S, Kubo N, Nakagawara A.
    Biochem Biophys Res Commun; 2009 Sep 11; 387(1):143-8. PubMed ID: 19576172
    [Abstract] [Full Text] [Related]

  • 10. DNp73 exerts function in metastasis initiation by disconnecting the inhibitory role of EPLIN on IGF1R-AKT/STAT3 signaling.
    Steder M, Alla V, Meier C, Spitschak A, Pahnke J, Fürst K, Kowtharapu BS, Engelmann D, Petigk J, Egberts F, Schäd-Trcka SG, Gross G, Nettelbeck DM, Niemetz A, Pützer BM.
    Cancer Cell; 2013 Oct 14; 24(4):512-27. PubMed ID: 24135282
    [Abstract] [Full Text] [Related]

  • 11. NEDDylation controls the target specificity of E2F1 and apoptosis induction.
    Aoki I, Higuchi M, Gotoh Y.
    Oncogene; 2013 Aug 22; 32(34):3954-64. PubMed ID: 23001041
    [Abstract] [Full Text] [Related]

  • 12. Suppression of acetylpolyamine oxidase by selected AP-1 members regulates DNp73 abundance: mechanistic insights for overcoming DNp73-mediated resistance to chemotherapeutic drugs.
    Bunjobpol W, Dulloo I, Igarashi K, Concin N, Matsuo K, Sabapathy K.
    Cell Death Differ; 2014 Aug 22; 21(8):1240-9. PubMed ID: 24722210
    [Abstract] [Full Text] [Related]

  • 13. p53 inactivation upregulates p73 expression through E2F-1 mediated transcription.
    Tophkhane C, Yang SH, Jiang Y, Ma Z, Subramaniam D, Anant S, Yogosawa S, Sakai T, Liu WG, Edgerton S, Thor A, Yang X.
    PLoS One; 2012 Aug 22; 7(8):e43564. PubMed ID: 22952705
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Targeting p73--a potential approach in cancer treatment.
    Slade N, Horvat A.
    Curr Pharm Des; 2011 Aug 22; 17(6):591-602. PubMed ID: 21391909
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Variation in transcriptional regulation of cyclin dependent kinase inhibitor p21waf1/cip1 among human bronchogenic carcinomas.
    Harr MW, Graves TG, Crawford EL, Warner KA, Reed CA, Willey JC.
    Mol Cancer; 2005 Jul 13; 4():23. PubMed ID: 16014176
    [Abstract] [Full Text] [Related]

  • 18. α-TEA cooperates with chemotherapeutic agents to induce apoptosis of p53 mutant, triple-negative human breast cancer cells via activating p73.
    Tiwary R, Yu W, Sanders BG, Kline K.
    Breast Cancer Res; 2011 Jan 07; 13(1):R1. PubMed ID: 21214929
    [Abstract] [Full Text] [Related]

  • 19. MicroRNA-361-3p promotes human breast cancer cell viability by inhibiting the E2F1/P73 signalling pathway.
    Hua B, Li Y, Yang X, Niu X, Zhao Y, Zhu X.
    Biomed Pharmacother; 2020 May 07; 125():109994. PubMed ID: 32092817
    [Abstract] [Full Text] [Related]

  • 20. A microRNA-dependent program controls p53-independent survival and chemosensitivity in human and murine squamous cell carcinoma.
    Ory B, Ramsey MR, Wilson C, Vadysirisack DD, Forster N, Rocco JW, Rothenberg SM, Ellisen LW.
    J Clin Invest; 2011 Feb 07; 121(2):809-20. PubMed ID: 21293058
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.